Blood clots are one of the most-feared risks of testosterone therapy — and one of the most preventable, if you act in the right order. Testosterone replacement therapy raises clot risk through two mechanisms: it stimulates red blood cell production (raising hematocrit, which thickens the blood) and it increases platelet aggregation (making clots form more readily). The reassuring part for anyone worried about it: this risk is largely preventable through a specific, evidence-based sequence of monitoring and protocol adjustments — and the risk itself is more modest and more manageable than vein-clinic warnings suggest.

This guide gives you the actual prevention plan: the front-loaded monitoring schedule, the dose and delivery levers that work before anyone reaches for a needle, the honest truth about phlebotomy and blood donation, and the warning signs that mean call a doctor now. For the broader risk picture, see our guides on high hematocrit on TRT and TRT side effects.

How TRT Raises Clot Risk and How Real It Actually Is

Understanding what you’re preventing makes the prevention plan make sense. Testosterone drives the bone marrow to produce more red blood cells, raising your hematocrit — the percentage of your blood made up of red cells. Higher hematocrit means thicker blood that flows less efficiently and clots more readily. Testosterone also modestly increases platelet aggregation, the clumping process that initiates clots. Together these are the basis for the venous thromboembolism (VTE) concern — clots that form in the veins, including deep vein thrombosis (DVT) and pulmonary embolism (PE).

Here is the honest risk picture, which most articles either exaggerate or skip. Testosterone-induced erythrocytosis carries a substantially lower clot risk than primary blood disorders like polycythemia vera, where venous thrombosis risk runs 13 times higher. The association between TRT-elevated hematocrit and actual clots is modest: the Tromsø Study found each 5% increase in hematocrit raised VTE risk by a hazard ratio of 1.33. A 2024 systematic review concluded that high-quality evidence directly linking testosterone-induced erythrocytosis to clots is actually lacking — the relationship is associative, not proven causal.

What is well-established: the risk concentrates in the first 6–12 months. A Journal of Urology analysis found men who developed secondary polycythemia on TRT had increased cardiovascular events and VTE specifically in the first year. That timing is why this entire prevention plan is front-loaded toward the beginning of therapy. The bottom line: this is a manageable risk, not a reason to avoid TRT — but not one to ignore either, especially in your first year and especially if you carry additional risk factors.

Step 1: Adjust Your Dose Before Anything Else

When hematocrit climbs on TRT, there is an evidence-based order of operations — and most articles get it wrong by jumping straight to blood donation. The first lever is your dose. The 2024 review in Endocrine Connections and American Urological Association guidance both identify dose reduction as the first-line response to rising hematocrit. Erythrocytosis is dose-dependent: the higher your testosterone peaks, the more red blood cell production the marrow drives. Lowering the dose — sometimes only modestly — frequently brings hematocrit back into range without any other intervention.

This is the single most underused lever in TRT clot prevention. Men reach for blood donation while leaving the actual driver — a dose that’s higher than they need, or peaks that are higher than necessary completely unaddressed. If your hematocrit is rising, the first conversation with your provider should be about your dose, not about scheduling a phlebotomy.

The action: If hematocrit trends above 50%, ask your provider whether your dose can be reduced while keeping your testosterone in an effective range. Many men are on more testosterone than they need for symptom relief, and a modest reduction often solves the blood-count problem.

Step 2: Change Your Delivery Method or Injection Frequency

The way testosterone enters your body affects hematocrit as much as the dose does — because what drives red blood cell production is the peak level, not just the total amount.

Intramuscular injections produce the largest hematocrit increases because they create high peak testosterone levels. One study documented a rise from 42.7% to 46.6% hematocrit on intramuscular testosterone. Transdermal gels and the nasal preparation produce much more modest increases, because they deliver testosterone more steadily without the sharp peaks.

Three adjustments flatten those peaks:

1. Switch from intramuscular to subcutaneous injection. Subcutaneous delivery produces lower, more stable peaks than deep intramuscular injection of the same dose.
2. Split your weekly dose into smaller, more frequent injections. Taking the same total weekly dose as two or three smaller injections instead of one large one flattens the peak-to-trough swing that drives erythrocytosis. This is one of the most effective adjustments and often resolves a borderline hematocrit problem.
3. Consider switching to a gel. For men whose hematocrit stays elevated despite injection adjustments, transdermal gel often resolves it entirely because of its steadier delivery profile.

The action: If dose reduction alone isn’t enough, work with your provider to split your injections more frequently or move to subcutaneous or transdermal delivery before escalating to phlebotomy.

Step 3: Follow a Front-Loaded Monitoring Schedule

You cannot prevent what you don’t measure. Because the clot risk concentrates in the first year, monitoring is front-loaded rather than annual.

The thresholds that matter, from AUA guidance and supporting research:

• Hematocrit above 50%: Investigate the cause. Consider whether sleep apnea, dehydration, altitude, or smoking are contributing alongside TRT.
• Hematocrit ≥52%: A retrospective study found increased cardiovascular and clot events specifically at this level, with no significant difference at 50% — the low-50s is where action begins.
• Hematocrit ≥54%: Reduce the dose or temporarily pause testosterone. This is the level at which intervention is clearly indicated.

The action: Get your baseline drawn before you start, then hold your provider to the 3-month and 6-month checks specifically — these are the ones most often skipped, and they fall inside the highest-risk window. For more on donation logistics, see our guide on how often to donate blood on testosterone.

Step 4: Use Phlebotomy Carefully and Know the Caveat

Therapeutic phlebotomy removing a unit of blood (about 500 mL) to lower hematocrit — is the most commonly recommended intervention. It works mechanically: remove red cells, hematocrit drops. For men with hematocrit at or above 54%, or with symptoms, it provides fast reduction.

Here is what most articles don’t tell you: there is no direct evidence that phlebotomy reduces clot risk in testosterone-induced erythrocytosis specifically. The recommendation is extrapolated from polycythemia vera — a different disease with a different mechanism. The 2024 Endocrine Connections review went further, arguing that periodic phlebotomy might in some cases increase thrombotic risk by activating hypoxia-sensing pathways and depleting iron — both of which can independently promote clotting.

This does not make phlebotomy wrong. It means phlebotomy should not be the automatic, first, or routine response. The evidence-based approach: try dose and delivery adjustment first, use phlebotomy when hematocrit is high enough to need fast action or when adjustments aren’t enough, and avoid turning it into an every-eight-weeks habit that leaves the underlying dose unaddressed.

The action: If phlebotomy is recommended, ask whether your dose and delivery have been optimized first. If you do donate, standard cadence is every 8 weeks, maximum 6 times per year but monitor for the problem in the next step.

Step 5: Avoid the Iron-Depletion Trap

Frequent phlebotomy or blood donation creates a problem most men don’t see coming, and it’s the clearest reason phlebotomy should be managed carefully.

Every unit of blood removed takes iron with it. Men who donate frequently to control hematocrit can drive their ferritin the body’s iron storage marker — to the floor. The symptoms of low ferritin are fatigue, brain fog, restless legs, poor exercise recovery, and low mood almost identical to the symptoms of low testosterone. Men routinely misattribute these to “TRT not working,” then either increase their dose (worsening the hematocrit problem) or abandon therapy entirely. The intervention meant to keep them safe ends up making them feel worse and clouding the picture.

How to avoid the trap:

• Monitor ferritin alongside hematocrit if you’re donating regularly. Ferritin below 30 ng/mL signals depletion.
• Treat crashing ferritin as a signal to address the dose driving the erythrocytosis — not as a reason to keep donating into iron deficiency.
• Don’t blindly supplement iron. Adding iron while continuing to drive red blood cell production can worsen hematocrit. Iron repletion in this context needs provider guidance.

A real scenario this prevents: a man on 200 mg/week donates blood every 8 weeks for a year to keep his hematocrit down, develops crushing fatigue and brain fog, assumes his testosterone is too low, and asks to increase his dose — when the actual fix was reducing his dose to stop the erythrocytosis at its source and letting his iron recover.

Step 6: Hydration, Sleep Apnea, and the Lifestyle Levers

Hydration the truth about it

 Staying well-hydrated helps, but know its limits. A hematocrit reading reflects two things: your actual red cell mass and the plasma volume it’s measured against. Dehydration concentrates the blood, raising the hematocrit percentage without any change in red cell count — “relative” erythrocytosis. Adequate water corrects that relative component and can lower a reading by a meaningful margin. But hydration does not reduce a genuinely elevated red cell mass. If TRT is driving real red blood cell production, water helps the reading at the margins — it is not the fix. Stay consistently hydrated, especially around lab draws and injection days, but don’t treat it as your prevention strategy.

Sleep apnea

 Untreated obstructive sleep apnea independently raises hematocrit by lowering nighttime oxygen, which stimulates red blood cell production — compounding TRT’s effect. Treating it with CPAP measurably lowers hematocrit (one finding showed roughly a 1.1% reduction) and removes a major compounding clot risk factor. If you snore heavily or wake unrefreshed, get evaluated — this is one of the most overlooked contributors to high hematocrit on TRT.

Smoking

Smoking raises hematocrit and independently increases clot risk. Cessation brings hematocrit toward non-smoker levels within a year.

Body composition and movement

 Higher BMI correlates with higher erythrocytosis risk — roughly 13% increased risk per BMI unit in one analysis. And prolonged immobility (long flights, long drives, extended bed rest) is an independent clot trigger. Stay mobile, particularly during your first year on TRT, and take movement breaks on long journeys.

Warning Signs: When to Seek Emergency Care

Prevention reduces risk; it doesn’t eliminate it. Know the signs of a clot that require immediate medical attention.

Deep vein thrombosis (DVT)  usually in the leg:

• Swelling in one leg (rarely both)
• Pain or tenderness, often in the calf, that may feel like cramping
• Warmth and redness or discoloration over the affected area

Pulmonary embolism (PE) — a clot that has traveled to the lungs (medical emergency):

• Sudden shortness of breath
• Sharp chest pain that worsens with deep breathing
• Rapid heart rate
• Coughing, sometimes with blood
• Lightheadedness or fainting

A PE is life-threatening and requires emergency care immediately — call emergency services, do not wait. If you develop one-sided leg swelling and pain, contact your provider the same day. Men in the first 6–12 months of TRT, and those with elevated hematocrit, should treat these symptoms with particular seriousness given the concentrated risk window.

Frequently Asked Questions

Can TRT cause blood clots?

TRT is associated with an increased risk of blood clots, primarily by raising hematocrit (thickening the blood) and increasing platelet aggregation. However, the evidence shows an association rather than proven direct causation, and the risk is lower than with primary blood disorders like polycythemia vera. The risk is concentrated in the first 6–12 months of therapy and is largely manageable through monitoring, dose adjustment, and addressing compounding factors like sleep apnea.

What hematocrit level is dangerous on TRT?

Hematocrit above 50% warrants investigation into the cause. Research found increased cardiovascular and clot events specifically at hematocrit ≥52%. The clear intervention threshold per AUA guidance is 54% — at that level, providers reduce the dose or temporarily pause testosterone. The low-50s is the zone where prevention shifts from monitoring to active intervention.

Does donating blood lower the risk of clots on TRT?

Donating blood (or therapeutic phlebotomy) lowers hematocrit mechanically, but there is no direct evidence it reduces clot risk in testosterone-induced erythrocytosis specifically — the recommendation is extrapolated from a different blood disorder. A 2024 review even raised the possibility that frequent phlebotomy could increase risk through iron depletion and hypoxia pathways. Use it as a second-line tool after dose and delivery adjustment, not as a routine first response, and monitor your ferritin.

Does drinking water lower hematocrit on TRT?

Hydration lowers the relative portion of a high hematocrit reading — the part caused by concentrated blood from dehydration — and can meaningfully improve a reading. But it does not reduce a genuinely elevated red blood cell mass. If your hematocrit is high because TRT is driving real red cell production, water helps at the margins but is not the solution. Stay hydrated, especially around lab draws, but rely on dose and delivery adjustments for true prevention.

How often should you get blood work on TRT?

Monitoring is front-loaded because clot risk concentrates early: baseline before starting, then at 3 months, 6 months, and 12 months in the first year, then annually thereafter — or every 3–6 months if you’ve had elevated readings. The 3-month and 6-month checks are the most important and the most commonly skipped, since they fall inside the highest-risk window.

Are blood clots more common with testosterone injections than gels?

Injections raise hematocrit more than gels because they create higher peak testosterone levels — one study showed intramuscular testosterone raising hematocrit from 42.7% to 46.6%, while gels and nasal preparations produce more modest increases. Splitting injections into smaller, more frequent doses, switching to subcutaneous injection, or moving to a gel all reduce the peaks that drive erythrocytosis and, by extension, the clot risk associated with it.

What are the warning signs of a blood clot on TRT?

For a deep vein thrombosis: swelling in one leg, calf pain or tenderness, and warmth or discoloration over the area. For a pulmonary embolism (a medical emergency): sudden shortness of breath, sharp chest pain that worsens with breathing, rapid heart rate, coughing (possibly with blood), and lightheadedness. A suspected pulmonary embolism requires emergency care immediately. One-sided leg swelling and pain warrant same-day medical contact.

Preventing blood clots on TRT starts with the right monitoring and the right protocol — not guesswork or routine blood draining. Book a consultation with TRTNYC to get baseline and scheduled hematocrit monitoring, a dose and delivery method matched to your risk profile, and a clear plan that keeps your blood count safe without compromising your results.